In The Highlighted Structure Which Cell Types Produce Testosterone

You're staring at a histology slide. Maybe it's for a class. Because of that, maybe you're prepping for boards. Maybe you just fell down a rabbit hole after reading about hormone replacement therapy. Even so, either way, you're looking at a cross-section of testicular tissue and someone — a professor, a textbook, a diagram — has highlighted a specific region. The question is simple: **which cells in that highlighted area actually make testosterone?

Short answer: Leydig cells. Also called interstitial cells. They sit in the connective tissue between the seminiferous tubules, and they're the body's primary testosterone factories.

But if you stop there, you miss the whole story. So because testosterone production isn't a solo act. It's a coordinated effort between cell types, signaling pathways, and feedback loops that most diagrams oversimplify. Let's walk through it properly Not complicated — just consistent..

What Are Leydig Cells and Where Do They Live

Leydig cells are the heavy lifters. They're large, polygonal, eosinophilic cells packed with smooth endoplasmic reticulum, mitochondria with tubulocristae, and lipid droplets — all the cellular machinery you'd expect in a steroid-producing cell. You'll find them in the interstitial space, the loose connective tissue between seminiferous tubules. That's the "highlighted structure" in most textbook figures: the pink-stained gaps between the tubules, not the tubules themselves Practical, not theoretical..

They originate from mesenchymal precursors during fetal development, differentiate under hCG stimulation (which mimics LH), go dormant after birth, then reactivate at puberty when the hypothalamic-pituitary-gonadal axis kicks into gear. In adults, they make up roughly 10–20% of testicular volume but produce over 95% of circulating testosterone in men.

The ultrastructure tells you everything

If you're looking at an EM image, you're not guessing. The smooth ER is abundant — that's where cholesterol gets converted to pregnenolone. The mitochondria with tubular cristae? On top of that, lipid droplets store cholesterol esters. That's where the side-chain cleavage enzyme (CYP11A1) lives. Think about it: this isn't trivia. Which means lipofuscin granules accumulate with age. It's how you distinguish Leydig cells from fibroblasts, macrophages, or endothelial cells in the same interstitial space.

Some disagree here. Fair enough It's one of those things that adds up..

Why This Matters Beyond Histology

You might wonder: why does a clinician care which cell type makes testosterone? Because when things go wrong, the cell type tells you what went wrong And it works..

Primary hypogonadism? But in secondary hypogonadism (pituitary tumor, opioid use, obesity), the Leydig cells are perfectly healthy — they're just not getting the LH signal. Same low testosterone. So leydig cell failure. LH skyrockets because the negative feedback is gone. Klinefelter syndrome, mumps orchitis, chemo/radiation toxicity, aging — the Leydig cells are damaged or depleted. Totally different workup.

And it's not just pathology. Now, understanding Leydig cell biology explains why hCG can stimulate testosterone production in men with secondary hypogonadism — it binds the same LH receptor. It explains why Leydig cell tumors produce testosterone (and sometimes estradiol via aromatase). It explains why testosterone drops with age: Leydig cell number declines, mitochondrial function drops, and oxidative stress increases. The cell is the mechanism Small thing, real impact..

How Testosterone Gets Made — Step by Step

We're talking about where most summaries quit. They say "Leydig cells make testosterone" and move on. But the pathway matters, because every step is a potential bottleneck The details matter here..

1. Cholesterol delivery

Testosterone is a steroid. All steroids come from cholesterol. Leydig cells get cholesterol three ways:

• De novo synthesis from acetate via HMG-CoA reductase (minor in adults)
• LDL receptor-mediated uptake of circulating LDL-cholesterol (major pathway)
• Hydrolysis of stored cholesterol esters in lipid droplets (rapid response)

This changes depending on context. Keep that in mind.

The rate-limiting step? No STAR, no testosterone. On top of that, congenital lipoid adrenal hyperplasia? Getting cholesterol from the outer to the inner mitochondrial membrane. LH binding → cAMP → PKA → STAR phosphorylation → cholesterol transfer. Think about it: sTAR mutation. Which means the Leydig cells are there. That said, they're full of cholesterol. Still, that's the STAR protein (Steroidogenic Acute Regulatory Protein). They just can't move it.

2. The mitochondrial conversions

Once cholesterol reaches the inner membrane, CYP11A1 (side-chain cleavage enzyme) chops off the side chain → pregnenolone. On top of that, this happens in the mitochondria. Pregnenolone then diffuses to the smooth ER Not complicated — just consistent..

3. The smooth ER pathway — two routes

From pregnenolone, there are two parallel pathways. The Δ5 pathway (pregnenolone → 17α-hydroxypregnenolone → DHEA → androstenediol → testosterone) and the Δ4 pathway (pregnenolone → progesterone → 17α-hydroxyprogesterone → androstenedione → testosterone). In human Leydig cells, the Δ4 pathway dominates It's one of those things that adds up. Surprisingly effective..

4. The final product

Testosterone diffuses out of the cell, binds to sex hormone-binding globulin (SHBG) and albumin in blood, and travels to target tissues. Worth adding: a small fraction stays free — that's the biologically active portion. In the testes, some testosterone acts locally on Sertoli cells (paracrine) and peritubular myoid cells. Most enters circulation.

The Supporting Cast: Cells That Don't Make Testosterone But Matter Anyway

Here's what most diagrams leave out. Leydig cells don't work in isolation.

Sertoli cells — the neighbors inside the tubules

Sertoli cells don't make testosterone. Practically speaking, they express FSH receptors, not LH receptors. But they're essential for spermatogenesis, and they need high intratesticular testosterone (100x serum levels) to support it. They also produce anti-Müllerian hormone (fetal life), inhibin B (negative feedback on FSH), and estradiol (via aromatase acting on Leydig-derived androgens). And they form the blood-testis barrier. No Sertoli cells → no sperm, even if Leydig cells are pumping out testosterone Simple, but easy to overlook..

Peritubular myoid cells

These smooth muscle-like cells surround seminiferous tubules. That's why testosterone maintains their function. Day to day, they have androgen receptors. They contract to move sperm along. They also produce growth factors that feed back on Leydig cells — a local regulatory loop Practical, not theoretical..

Macrophages and immune cells

Testicular macrophages sit right next to Leydig cells. They produce 25-hydroxycholesterol, a cholesterol derivative that can bypass STAR and enter mitochondria directly. They also secrete cytokines (TNF-α, IL-1, IL-6) that suppress Leydig cell steroidogenesis during inflammation. That's why orchitis tanks testosterone — it's not just damage, it's active suppression.

And yeah — that's actually more nuanced than it sounds Not complicated — just consistent..

Endothelial cells and vascular supply

Leydig cells are highly vascularized. Endothelial cells produce nitric oxide, which can inhibit CYP1

Endothelial cells and the vascular niche

The capillary network that envelopes each Leydig cell is more than a passive conduit; it actively shapes steroidogenic output. They synthesize cholesterol‑ester‑hydrolase, releasing free cholesterol that can be taken up by Leydig cells via scavenger receptors (SR‑B1). Endothelial cells line the sinusoids with a fenestrated phenotype that permits rapid exchange of cholesterol and lipid‑derived substrates. Worth including here, they secrete endothelin‑1, a peptide that, at physiologic concentrations, augments cAMP production in Leydig cells and thereby amplifies STAR transcription. Conversely, excessive endothelin‑1, often observed in fibrotic or hypertensive testes, contributes to a blunted steroidogenic response.

Nitric oxide (NO) generated by endothelial nitric‑oxide synthase (eNOS) exerts a dual effect. Worth adding: low‑grade NO enhances mitochondrial respiration and supports the activity of CYP11A1, while high concentrations, frequently encountered during inflammatory states, inhibit cholesterol side‑chain cleavage by binding to the heme‑containing active site of CYP11A1. This delicate balance explains why chronic systemic inflammation can precipitate a drop in serum testosterone without any direct Leydig‑cell pathology.

Cholesterol trafficking and lipid microdomains

Leydig cells rely on a tightly regulated pool of cholesterol that originates from three main sources:

1. Circulating LDL – taken up through LDL‑R after hepatic synthesis; the lipoprotein particle delivers cholesterol esters that are hydrolyzed by neutral cholesterol ester hydrolase (NCEH) in the cytosol.
2. HDL‑mediated exchange – HDL picks up excess cholesterol from Leydig cells and returns it to the liver; this reverse‑cholesterol flux helps maintain a dynamic equilibrium.
3. Intracellular synthesis – a fraction of cholesterol is generated de novo via the mevalonate pathway, a process stimulated by insulin‑like growth factor‑1 (IGF‑1) and suppressed by AMPK activation.

These sources converge in lipid microdomains enriched in caveolin‑1, which serve as platforms for the assembly of the steroidogenic machinery. Disruption of caveolin‑1, as seen in certain genetic knock‑out models, leads to fragmented microdomains, impaired STAR localization, and consequently reduced testosterone synthesis.

The official docs gloss over this. That's a mistake.

Paracrine amplification loops

Beyond the immediate cellular neighbors already mentioned, a cascade of paracrine signals fine‑tunes steroidogenesis:

• Growth factors: IGF‑1 released by Sertoli cells and peritubular myoid cells activates the PI3K‑AKT pathway in Leydig cells, enhancing expression of both STAR and CYP17A1.
• Neuropeptides: Substance P, derived from sensory nerve endings that innervate the testis, can stimulate cAMP generation in Leydig cells, providing a neuro‑endocrine boost during acute stress.
• Cytokine cross‑talk: Interleukin‑10, produced by resident macrophages, suppresses the pro‑inflammatory cascade while modestly up‑regulating CYP11A1 transcription, illustrating a nuanced immune‑endocrine interplay.

These signals are not static; they fluctuate with circadian rhythms, seasonal breeding cues, and acute infections, underscoring the dynamic nature of the endocrine axis.

Age‑related decline and pathological states

With advancing age, several variables converge to diminish testosterone output:

• Reduced LDL‑R expression limits cholesterol delivery.
• Impaired mitochondrial dynamics lead to diminished ATP generation, compromising the energy‑intensive steps of steroidogenesis.
• Accumulation of senescent cells in the interstitium releases persistent pro‑inflammatory cytokines that chronically suppress Leydig cell activity.

Pathologically, conditions such as primary testicular failure (e.g., Klinefelter syndrome) directly damage Leydig cells, while secondary hypogonadism stems from pituitary or hypothalamic dysfunction, reducing LH pulsatility.

…further suppression of gonadotropin‑releasing hormone (GnRH) pulsatility from the hypothalamus, which in turn diminishes LH secretion and perpetuates low intratesticular testosterone. This feed‑forward loop helps explain why aging men often exhibit a disproportionate rise in estradiol despite falling testosterone levels.

Therapeutic and preventive strategies

1. Targeting cholesterol delivery – Pharmacologic up‑regulation of LDL‑R (e.g., via PCSK9 inhibitors) or supplementation with phospholipid‑rich HDL mimetics can restore substrate availability in aged Leydig cells.
2. Modulating intracellular cholesterol synthesis – Low‑dose statins, when combined with IGF‑1 analogues, have shown in preclinical models to fine‑tune the mevalonate pathway without compromising essential isoprenoid products needed for steroidogenesis.
3. Enhancing microdomain integrity – Small‑molecule stabilizers of caveolin‑1 (such as cavtratin peptides) or gene‑therapy approaches that restore caveolin‑1 expression improve STAR anchoring and boost acute steroid output.
4. Paracrine pathway modulation –
   • IGF‑1 mimetics or AKT activators amplify STAR and CYP17A1 transcription.
   • Controlled delivery of substance P analogues can provide a short‑term cAMP surge useful in assisted reproductive protocols.
   • IL‑10‑based biologics or macrophage‑targeted nanocarriers temper chronic inflammation while preserving basal CYP11A1 activity.
5. Counteracting senescence – Senolytic agents (e.g., dasatinib + quercetin) reduce the burden of pro‑inflammatory interstitial cells, thereby lowering chronic cytokine suppression of Leydig function.
6. Lifestyle and metabolic interventions – Regular resistance exercise elevates endogenous IGF‑1 and improves mitochondrial oxidative capacity; caloric restriction or intermittent fasting activates AMPK, which, paradoxically, when modulated intermittently, can enhance cholesterol efflux from lipid droplets without impairing steroidogenic enzyme expression.

Conclusion

Testosterone synthesis in Leydig cells is the product of a tightly orchestrated network that balances cholesterol acquisition, intracellular lipid handling, and spatially organized enzymatic complexes within caveolin‑1‑rich microdomains. This core machinery is continuously fine‑tuned by a multilayered paracrine milieu—growth factors, neuropeptides, and immune cytokines—that integrates systemic metabolic status, neural input, and immune surveillance. So naturally, therapeutic avenues that simultaneously replenish cholesterol substrates, preserve microdomain integrity, modulate key paracrine signals, and alleviate chronic inflammation offer a rational path to restore or sustain testicular androgen production. On the flip side, age‑related declines in LDL‑R function, mitochondrial efficiency, and rising senescent‑cell burden disrupt this equilibrium, shifting the testosterone/estradiol axis toward relative estrogen excess and further dampening GnRH/LH drive. Continued dissection of these intersecting pathways will not only illuminate the physiology of male reproductive aging but also inspire precision interventions for hypogonadal states across the lifespan.

We're talking about where a lot of people lose the thread.